Tech Company Financing Transactions

Selecta Biosciences Funding Round

OrbiMed, Flagship Pioneering and NanoDimension joined a $15 million Series C venture round for Selecta Biosciences. The round was announced on 4/5/2010.

Transaction Overview

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

480 Arsenal St.
Watertown, MA 02472
USA

Phone

(617) 923-1400

Website

www.selectabio.com

Email Address

[email protected]

Overview

Selecta Biosciences, Inc. (NASDAQ: SELB) is a biopharmaceutical company developing an entirely new class of targeted vaccines that induces an antigen-specific immune activation or antigen-specific immune tolerance for therapeutic and prophylactic applications.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Werner Cautreels

        

Chief Financial Officer

John Leaman

        

Chief Medical Officer

Earl Sands

        

Chief Operating Officer

Lloyd Johnston

        

Chief Scientific Officer

Takashi Kishimoto

        

VP - Bus. Development

Stephen Smolinski

        

VP - General Counsel

David Abraham

        

Browse more venture capital transactions:

Prev: 4/5/2010: Shocking Technologies venture capital transaction
Next: 4/5/2010: Altheos venture capital transaction

Share this article

About Our VC Transactions Data

Our team works diligently to report on all VC transactions involving tech companies. VC investment data records on this site are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary